null

null

null

null

null

null

null

null

null

Minimal long-term debt; primarily equity-financed small-cap biotech; 20% rate rise has negligible interest expense impact given near-zero leverage

Low direct sensitivity; primary risk is higher discount rates compressing DCF valuation and making equity raises more dilutive

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-use bioreactor components (China manufacturing) and specialized raw biologics materials (limited EU/US CDMO suppliers) are top chokepoints

Minimal international revenue; USD-denominated operations dominate; sovereign currency devaluation exposure is negligible at current stage

Predominantly US-based operations in Bryan, TX; international revenue near zero; essentially no multi-currency devaluation exposure

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on specialized CDMO equipment vendors and biologics raw material suppliers; substitution is feasible but time-consuming (6-18 months)

Contract development and manufacturing organization (CDMO) providing biologics manufacturing services to pharma/biotech clients

Cloud infrastructure termination would disrupt ERP, data management, and client communication but manufacturing operations are on-premise; moderate 30-day risk

Moderate API coupling risk; reliance on enterprise lab software and ERP platforms; switching costs real but not existential

Low Howey risk; revenue model is fee-for-service manufacturing contracts, not investment schemes; no token or profit-sharing structure

Very High

Limited GDPR exposure given minimal EU client base; CCPA exposure moderate for employee/vendor data; no large consumer data sets held

Negligible antitrust risk; small market share in fragmented biologics CDMO market; no dominant position in any segment

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional/project-based manufacturing contracts; recurring revenue under multi-year supply agreements estimated below 30% of total

Fee-for-service biologics manufacturing; milestone payments; potential future royalty or licensing streams from FastPharming platform

Cost-plus and value-based project pricing; vulnerable to raw material inflation and client budget cuts; limited pricing power as emerging CDMO

Low-to-moderate; iBio competes on capacity and speed vs. larger CDMOs; price increases risk client attrition given alternatives

541.8% Gross Margin (Premium (>60%))

No meaningful free-rider leakage; services are proprietary and contracted; client churn risk tied to clinical trial failures or budget reductions

Revenue growth is headcount-near-linear; biologics manufacturing requires skilled labor scaling with capacity; limited sublinear leverage short-term

High marginal cost of growth; capacity expansion requires capex and headcount; gross margin improvement depends on utilization rate gains

Not applicable; iBio is not a franchise model

At 10x scale, CAC likely improves via reputation/BD leverage, but unit economics remain constrained by fixed facility and labor costs

No meaningful network effects; CDMO services are linear; client success drives referrals but no platform flywheel exists

AI displacement risk low in near term; biologics manufacturing requires physical assets and skilled bioprocess scientists not easily automated

Moderate resilience; pharma/biotech R&D spending can be cut in severe downturns but biologics pipeline demand is relatively inelastic

Small-to-mid-size biopharmaceutical and biotech companies outsourcing biologics drug substance manufacturing

Government and defense agencies (e.g., BARDA-type contracts) for medical countermeasure manufacturing; concentration risk if one contract dominates

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

4.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001420720

IBIO